Migräne und Hormonbehandlung

Eine Hormontherapie erhöht bekanntermaßen das Thrombembolierisiko. Migräne mit Aura erhöht bei Frauen unter 45 Jahren das Risiko für einen Schlaganfall um ca. das Doppelte. Zwei Fakten, die deutlich machen, dass bei Frauen mit Migräne, bei denen eine Hormontherapie indiziert ist, einiges zu beachten ist. Dieser Beitrag informiert u. a. über Vor- und Nachteile einer Hormongabe bei Migränepatientinnen in verschiedenen Lebensphasen.

• Literatur

• 1 Westhoff CL, Heartwell SF, Edwards S. et al. Oral contraceptive discontinuation: do side effects matter?. Am J Obstet Gynecol 2007; 196: 412.e1-412.e6
• 2 Loder EW, Buse DC, Golub JR. Headache and combination estrogen-progestin oral contraceptives: integrating evidence, guidelines, and clinical practice. Headache 2005; 45: 224-231
• 3 MacGregor EA. Contraception and headache. Headache 2013; 53: 247-276
• 4 Aegidius K, Zwart JA, Hagen K. et al. Oral contraceptives and increased headache prevalence: the Head-HUNT Study. Neurology 2006; 66: 349-353
• 5 Granella F, Sances G, Pucci E. et al. Migraine with aura and reproductive life events: a case control study. Cephalalgia 2000; 20: 701-707
• 6 Cupini LM, Matteis M, Troisi E. et al. Sex-hormone-related events in migrainous females. A clinical comparative study between migraine with aura and migraine without aura. Cephalalgia 1995; 15: 140-144
• 7 Morotti M, Remorgida V, Venturini PL. et al. Progestogen-only contraceptive pill compared with combined oral contraceptive in the treatment of pain symptoms caused by endometriosis in patients with migraine without aura. Eur J Obstet Gynecol Reprod Biol 2014; 179: 63-68
• 8 Nappi RE, Merki-Feld GS, Terreno E. et al. Hormonal contraception in women with migraine: is progestogen-only contraception a better choice?. J Headache Pain 2013; 14: 66
• 9 Nappi RE, Terreno E, Sances G. et al. Effect of a contraceptive pill containing estradiol valerate and dienogest (E2 V/DNG) in women with menstrually-related migraine (MRM). Contraception 2013; 88: 369-375
• 10 Sulak PJ, Willis SA, Kuehl TJ. et al. Headaches and Oral Contraceptives: Impact of Eliminating the Standard 7-Day Placebo Interval. Headache 2007; 47: 27-37
• 11 Archer DF, Jensen JT, Johnson JV. et al. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results. Contraception 2006; 74: 439-445
• 12 Sacco S, Merki-Feld GS, Ægidius KL. et al. Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). J Headache Pain 2017; 18: 108
• 13 Donaghy M, Chang CL, Poulter NR. Duration, frequency, recency, and type of migraine and the risk of ischaemic stroke in women of childbearing age. J Neurol Neurosurg Psychiatry 2002; 73: 747-750
• 14 Weill A, Dalichampt M, Raguideau F. et al. Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study. BMJ 2016; 353: i2002
• 15 Gillum LA, Mamidipudi SK, Johnston SC. Ischemic stroke risk with oral contraceptives: A meta-analysis. JAMA 2000; 284: 72-78
• 16 Lidegaard O, Lokkegaard E, Jensen A. et al. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 2012; 366: 2257-2266
• 17 Hormonal Contraception. Guideline of the DGGG, SGGG and OEGGG (S3-Level, AWMF Registry No. 015/015, January 2020). Online (Stand: 05.05.2023): https://pubmed.ncbi.nlm.nih.gov/33623171/
• 18 Stewart WF, Lipton RB, Celentano DD. et al. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA 1992; 267: 64-69
• 19 Sacco S, Merki-Feld GS, Ægidius KL. et al. Effect of exogenous estrogens and progestogens on the course of migraine during reproductive age: a consensus statement by the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESCRH). J Headache Pain 2018; 19: 76
• 20 Mattsson P. Hormonal factors in migraine: a population-based study of women aged 40 to 74 years. Headache 2003; 43: 27-35
• 21 Neri I, Granella F, Nappi R. et al. Characteristics of headache at menopause: a clinico-epidemiologic study. Maturitas 1993; 17: 31-37
• 22 Nattero G. Menstrual headache. Adv Neurol 1982; 33: 215-226
• 23 Cull RE. Investigation of late-onset migraine. Scott Med J 1995; 40: 50-52
• 24 Lichten EM, Lichten JB, Whitty A. et al. The confirmation of a biochemical marker for womenʼs hormonal migraine: the depo-estradiol challenge test. Headache 1996; 36: 367-371
• 25 Kudrow L. The relationship of headache frequency to hormone use in migraine. Headache 1975; 15: 36-40
• 26 Stryker JC. Use of hormones in women over forty. Clin Obstet Gynecol 1977; 20: 155-164
• 27 Granella F, Sances G, Zanferrari C. et al. Migraine without aura and reproductive life events: a clinical epidemiological study in 1300 women. Headache 1993; 33: 385-389
• 28 Nappi RE, Sances G, Sommacal A. et al. Different effects of tibolone and low-dose EPT in the management of postmenopausal women with primary headaches. Menopause 2006; 13: 818-825
• 29 Misakian AL, Langer RD, Bensenor IM. et al. Postmenopausal hormone therapy and migraine headache. J Womens Health (Larchmt) 2003; 12: 1027-1036
• 30 Aegidius KL, Zwart JA, Hagen K. et al. Hormone replacement therapy and headache prevalence in postmenopausal women. The Head-HUNT study. Eur J Neurol 2007; 14: 73-78
• 31 Facchinetti F, Nappi RE, Tirelli A. et al. Hormone supplementation differently affects migraine in postmenopausal women. Headache 2002; 42: 924-929
• 32 Nappi RE, Cagnacci A, Granella F. et al. Course of primary headaches during hormone replacement therapy. Maturitas 2001; 38: 157-163
• 33 Glaser R, Dimitrakakis C, Trimble N. et al. Testosterone pellet implants and migraine headaches: a pilot study. Maturitas 2012; 71: 385-388
• 34 Kurth T, Winter AC, Eliassen AH. et al. Migraine and risk of cardiovascular disease in women: prospective cohort study. BMJ 2016; 353: i2610
• 35 Tietjen GE, Maly EF. Migraine and Ischemic Stroke in Women. A Narrative Review. Headache 2020; 60: 843-863
• 36 Hu X, Zhou Y, Zhao H. et al. Migraine and the risk of stroke: an updated meta-analysis of prospective cohort studies. Neurol Sci 2017; 38: 33-40
• 37 Champaloux SW, Tepper NK, Monsour M. et al. Use of combined hormonal contraceptives among women with migraines and risk of ischemic stroke. Am J Obstet Gynecol 2017; 216: 489.e1-489.e7
• 38 Schürks M, Rist PM, Bigal ME. et al. Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ 2009; 339: b3914
• 39 Stute P. NAMS-Positionspapier zur Hormonersatztherapie 2022. Journal für Gynäkologische Endokrinologie/Schweiz 2022; 25: 205-206
• 40 Anonym WHO Guidelines approved by the Guidelines Review Committee. In: Medical Eligibility Criteria for Contraceptive Use. Geneva: World Health Organization; 2015
• 41 Serfaty D. Update on the contraceptive contraindications. J Gynecol Obstet Hum Reprod 2019; 48: 297-307
• 42 Diener HC, Förderreuther S, Kropp P. et al. Therapie der Migräneattacke und Prophylaxe der Migräne. S1-Leitlinie, 2022, DGN und DMKG. In: Deutsche Gesellschaft für Neurologie, Hrsg. Leitlinien für Diagnostik und Therapie in der Neurologie Online (Stand: 05.05.2023): http://www.dgn.org/leitlinien
• 43 Øie LR, Kurth T, Gulati S. et al. Migraine and risk of stroke. J Neurol Neurosurg Psychiatry 2020; 91: 593-604
• 44 Sheikh HU, Pavlovic J, Loder E. et al. Risk of Stroke Associated With Use of Estrogen Containing Contraceptives in Women With Migraine: A Systematic Review. Headache 2018; 58: 5-21